Bernhard Landwehrmeyer

Last updated

Bernhard Landwehrmeyer
FRCP
Landwehrmeyer B neurologist.jpg
Landwehrmeyer in 2022
Born
Georg Bernhard Landwehrmeyer

1960 (age 64–65)
Freiburg, Germany
Alma mater
Known forResearch into neurodegeneration, particularly Huntington disease
Scientific career
Fields
Institutions UKU
Thesis  (1990)
Doctoral advisor R. Jung
Website www.uniklinik-ulm.de/neurologie/sprechstunden-ambulanzen/morbus-huntington.html

Georg Bernhard Landwehrmeyer FRCP is a German neurologist and neuroscientist in the field of neurodegeneration primarily focusing on Huntington's disease. [1] Landwehrmeyer is a professor of neurology at Ulm University Hospital. He was one of the founders of the European Huntington's Disease Network (EHDN) in 2004 and was chairman of its executive committee until 2014. [1]

Contents

Education and career

Landwehrmeyer received his MD degree and Doctoral Degree from the Albert Ludwigs University of Freiburg, Germany, where he also completed a residency in neurology, research training in neuropathology and molecular pharmacology, and a residency in neurology and psychiatry. [1] [2] Landwehrmeyer studied at the Royal Victoria Hospital, Belfast and Kantonsspital St. Gallen, Basel. He was a post-Doc from 1993 to 1995 at Massachusetts General Hospital, Harvard Medical School. During 1995–1999, he was a staff member at Albert Ludwigs University of Freiburg, Department of Neurology & Psychiatry. In 1999, he received his Board certification in Neurology and has been a full professor since 2000. [3] He served as principal investigator in numerous HD clinical trials [4] [5] [6] and observational studies [7] [8] and is the principal investigator of the CHDI-sponsored Enroll-HD study. [3]

Research

Landwehrmeyer started working on Huntington's Disease (HD) in 1993 when he started a postdoc at Massachusetts General Hospital (MGH) with Anne B. Young, then Chief of Neurology, a couple of months before the HD gene and the HD expansion mutation was discovered. He went to Venezuela with Anne and Nancy Wexler several times, and was alerted to stimulating HD field studies aside from work at the bench. [9]

In 2000 he was appointed full Professor of Neurology, 'Clinical Neurobiology,' at the University of Ulm and was given the opportunity to organize (together with Albert Ludolph, the chairperson of the Department of Neurology at the University of Ulm, who initiated the work) the first large (>500 participants), long-term (3-year randomized clinical trial, followed by a blinded extension) multicenter European phase III HD trial. This collaboration led to forming the European HD Network (EHDN) in 2003–2004, funded by CHDI Foundation, a philanthropic US-American organization. He is the founding chair of the executive committee of EHDN and served in this capacity in 2004–2014. [10] He continues to serve as leader of the EHDN project at the University of Ulm. [11]

The large prospective observational cohort study REGISTRY, [7] conducted by EHDN, recruiting more than 15,000 participants, merged with the cohort study of the Huntington Study Group (HSG) to form Enroll-HD study [8] in 2011, which is still ongoing. Landwehrmeyer serves as the Principal Investigator (PI) of Enroll-HD, a worldwide platform to facilitate HD research and to conduct prospective, observational HD cohort studies for HD families. [8]

His main area of interest is neurodegenerative diseases, such as Huntington disease, [12] [13] [14] Parkinsonian disorders (including progressive supranuclear palsy [15] and multiple system atrophy), [16] frontotemporal lobar degeneration (FTD), [17] [18] [19] and amyotrophic lateral sclerosis [20] [21] [22] (ALS). Other topics on which he published include neuroimaging [23] [24] and pain. [25] [26] Vast majority of Landwehrmeyer's publications are devoted to various aspects of neurobiology of HD, [27] [28] including its genetics, [29] [9] genetic modifiers. [30]

Bernhard Landwehrmeyer was involved in almost all RCTs in HD conducted in Europe since 1999, often serving as coordinating PI or national lead investigator. He contributed to Track-HD [31] and Track-ON HD, [32] two influential observational studies in HD, and to 26 phase I-III clinical trials, primarily in HD, [33] [34] [35] including a first-in-man intrathecal application of antisense oligonucleotides ASO to silence huntingtin gene expression evaluating the safety, tolerability, and efficacy of intrathecally administered agents [36] as well as non-pharmacological interventions, studying the impact of physical activity and exercise in people with HD.

Landwehrmeyer directs the HD Center Ulm, where a multi-disciplinary team takes care of over 700 with HD in an out-patient setting where more than 600 agreed to participate in Enroll-HD. This multi-disciplinary center provides genetic counselling, clinical in- and out-patient services as well as rehabilitation for HD affected families along with basic and translational science. In addition, the HD Center South (in Taufkirchen/Vils) offers 19 in-patient beds dedicated to HD in the setting of a psychiatric hospital and 20-25 beds for in-patient rehab at Ulm.

Landwehrmeyer is also a member of the Scientific Advisory Board (Wissenschaftlicher Beirat) of the German Huntington’s Disease Association (Deutsche Huntington-Hilfe e.V., DHH). [37] In this role, he regularly provides expert updates on research developments to the Huntington’s patient community, often together with Carsten Saft.

Landwehrmeyer's most significant publications are:

Landwehrmeyer is a Fellow of the Royal College of Physicians and a member of several learned medical societies.

As of April 2022, Landwehrmeyer had authored over 300 publications, with over 15,000 citations for his research. [38]

Research awards

Non-research awards

Personal life

Landwehrmeyer currently lives in Ulm, Germany. His father, Richard Landwehrmeyer  [ de ], was a German librarian. From 1972 to 1987 he headed the University Library of Tübingen [45] and from 1987 to 1995 the State Library of Berlin as Director General.

References

  1. 1 2 3 Landwehrmeyer, G Bernhard (2012). "Interview: Following a standard of care for Huntington's disease" . Neurodegener Dis Manag. 2 (2): 159–63. doi:10.2217/nmt.12.3.
  2. ↑ Deeprose, Catherine (2 July 2021). "Taking Stock: Interview with G. Bernhard Landwehrmeyer" (PDF). EHDN News. No. 43. Retrieved 30 April 2022.
  3. 1 2 "Executive Committee - Public Documents". European Huntington's Disease Network. Retrieved 30 April 2022.
  4. ↑ "An Exploratory Clinical Trial in Early Stage Huntington's Disease Patients With SEN0014196 (PADDINGTON)". ClinicalTrials.gov . United States National Library of Medicine. 24 November 2015. Retrieved 1 May 2022. ... Principal Investigator: Bernhard G Landwehrmeyer, MD, PhD European Huntington's Disease Network ...'
  5. ↑ "Imaging of PDE10A Enzyme Levels in Huntington's Disease Gene Expansion Carriers and Healthy Controls With PET. (PEARL-HD)". ClinicalTrials.gov . United States National Library of Medicine. 31 May 2016. Retrieved 1 May 2022. ... Principal Investigator: Bernhard Landwehrmeyer, MD, PhD Ulm University Hospital ...'
  6. ↑ "Effects of Pregabalin on Mechanical Hyperalgesia". ClinicalTrials.gov . United States National Library of Medicine. 4 April 2007. Retrieved 1 May 2022.
  7. 1 2 "REGISTRY - an Observational Study of the European Huntington's Disease Network (EHDN)". ClinicalTrials.gov . United States National Library of Medicine. 14 September 2017. Retrieved 1 May 2022. ... Principal Investigator: Bernhard Landwehrmeyer, Professor University Hospital of Ulm / Dept. of Neurology ...'
  8. 1 2 3 "Enroll -HD: A Prospective Registry Study in a Global Huntington's Disease Cohort". ClinicalTrials.gov . United States National Library of Medicine. 29 March 2022. Retrieved 1 May 2022. ... Principal Investigator: Bernhard G Landwehrmeyer, MD, PhD University of Ulm ...'
  9. 1 2 Landwehrmeyer, G. Bernhard; McNeil, Sandra M.; Dure, Leon S. IV; Ge, Pei; Aizawa, Hitoshi; Huang, Qin; Ambrose, Christine M.; Duyao, Mabel P.; Bird, Edward D.; Bonilla, Ernesto; Young, Margot de; Avila-Gonzales, Alejandro J.; Wexler, Nancy S.; DiFiglia, Marian; Gusella, James F.; MacDonald, Marcy E.; Penney, John B.; Young, Anne B.; Vonsattel, Jean-Paul (1995). "Huntington's disease gene: regional and cellular expression in brain of normal and affected individuals" . Ann Neurol. 37 (2): 218–30. doi:10.1002/ana.410370213. PMID   7847863. S2CID   40930776.
  10. ↑ Townhill, Jenny; McLean, Tim; Levey, Jamie; Rosser, Anne; Weydt, Patrick; Orth, Michael; Capper-Loup, Christine (2021). "F46 The European huntington's disease network" . Journal of Neurology, Neurosurgery, and Psychiatry. 92 (1): 218–30. doi:10.1136/jnnp-2021-EHDN.89. S2CID   239647435.
  11. ↑ "Das Team der Morbus Huntington Sprechstunde". Universitätsklinikum Ulm  [ de ] (in German). Retrieved 2 May 2022.
  12. ↑ van der Burg, Jorien M M; Gardiner, Sarah L; Ludolph, Albert C; Landwehrmeyer, G Bernhard (2017). "Body weight is a robust predictor of clinical progression in Huntington disease". Ann Neurol. 82 (3): 479–483. doi:10.1002/ana.25007. PMID   28779551. S2CID   20730952.
  13. ↑ Langbehn, Douglas R; Stout, Julie C; Gregory, Sarah; Mills, James A; Durr, Alexandra; Leavitt, Blair R; Roos, Raymund A C; Long, Jeffrey D; Owen, Gail; Johnson, Hans J; Borowsky, Beth; Craufurd, David; Reilmann, Ralf; Landwehrmeyer, G Bernhard (2019). "Association of CAG Repeats With Long-term Progression in Huntington Disease". JAMA Neurol. 76 (11): 1375–1385. doi:10.1001/jamaneurol.2019.2368. PMC   6692683 . PMID   31403680.
  14. ↑ Lunkes, Astrid; Lindenberg, Katrin S; Ben-Haı̈em, Léa; Weber, Chantal; Devys, Didier; Landwehrmeyer, G Bernhard; Mandel, Jean-Louis; Trottier, Yvon (2002). "Proteases Acting on Mutant Huntingtin Generate Cleaved Products that Differentially Build Up Cytoplasmic and Nuclear Inclusions". Molecular Cell. 10 (2): 259–269. doi: 10.1016/S1097-2765(02)00602-0 . PMID   12191472.
  15. ↑ Brown, Richard G; Lacomblez, Lucette; Landwehrmeyer, Bernard G (2010). "Cognitive impairment in patients with multiple system atrophy and progressive supranuclear palsy" . Brain. 133 (8): 2382–2393. doi: 10.1093/brain/awq158 . PMID   20576697.
  16. ↑ Süssmuth, Sigurd D; Uttner, Ingo; Landwehrmeyer, Bernhard; Pinkhardt, Elmar H; Brettschneider, Johannes; Petzold, Axel; Kramer, Bernd; Schulz, Jörg B; Palm, Christian; Otto, Markus; Ludolph, Albert C; Kassubek, Jan; Tumani, Hayrettin (2010). "Differential pattern of brain-specific CSF proteins tau and amyloid-beta in Parkinsonian syndromes" . Mov Disord. 25 (9): 1284–8. doi:10.1002/mds.22895. PMID   20589870. S2CID   40634639.
  17. ↑ Otto, M; Ludolph, A C; Landwehrmeyer, B; Förstl, H; Diehl-Schmid, J; Neumann, M; Kretzschmar, H A; Schroeter, M; Kornhuber, J; Danek, A; FTLD consortium (2011). "Konsortium zur Erforschung der frontotemporalen Lobärdegeneration" . Der Nervenarzt (in German). 82 (1002): 1002–1005. doi:10.1007/s00115-011-3261-3. PMID   21805118.
  18. ↑ Frings, Lars; Mader, Irina; Landwehrmeyer, G Bernhard; Weiller, Cornelius; Hüll, Michael; Huppertz, Hans-Jürgen (2011). "Quantifying change in individual subjects affected by frontotemporal lobar degeneration using automated longitudinal MRI volumetry". Hum Brain Mapp. 33 (7): 1526–35. doi:10.1002/hbm.21304. PMC   6869947 . PMID   21618662.
  19. ↑ Denk, Johannes; Oberhauser, Felix; Kornhuber, Johannes; Wiltfang, Jens; Fassbender, Klaus; Schroeter, Matthias L; Volk, Alexander E; Diehl-Schmid, Janine; Prudlo, Johannes; Danek, Adrian; Landwehrmeyer, Bernhard; Lauer, Martin; Otto, Markus; Jahn, Holger (2018). "Specific serum and CSF microRNA profiles distinguish sporadic behavioural variant of frontotemporal dementia compared with Alzheimer patients and cognitively healthy controls". PLOS ONE. 13 (5): e0197329. Bibcode:2018PLoSO..1397329D. doi: 10.1371/journal.pone.0197329 . PMC   5945001 . PMID   29746584.
  20. ↑ Münch, C; Ebstein, M; Seefried, U; Zhu, B; Stamm, S; Landwehrmeyer, G B; Ludolph, A C; Schwalenstöcker, B; Meyer, T (2002). "Alternative splicing of the 5′-sequences of the mouse EAAT2 glutamate transporter and expression in a transgenic model for amyotrophic lateral sclerosis". J Neurochem. 82 (3): 594–603. doi: 10.1046/j.1471-4159.2002.01012.x . PMID   12153483. S2CID   26006717.
  21. ↑ Steinacker, Petra; Verde, Federico; Fang, Lubin; Feneberg, Emily; Oeckl, Patrick; Roeber, Sigrun; Anderl-Straub, Sarah; Danek, Adrian; Diehl-Schmid, Janine; Fassbender, Klaus; Fliessbach, Klaus; Foerstl, Hans; Giese, Armin; Jahn, Holger; Kassubek, Jan; Kornhuber, Johannes; Landwehrmeyer, G Bernhard (2002). "Chitotriosidase (CHIT1) is increased in microglia and macrophages in spinal cord of amyotrophic lateral sclerosis and cerebrospinal fluid levels correlate with disease severity and progression". Journal of Neurology, Neurosurgery, and Psychiatry. 89 (3): 239–247. doi:10.1136/jnnp-2017-317138. PMID   29142138. S2CID   3411700.
  22. ↑ van Rheenen, Wouter; Shatunov, Aleksey; Dekker, Annelot M (2016). "Genome-wide association analyses identify new risk variants and the genetic architecture of amyotrophic lateral sclerosis". Nat Genet. 48 (9): 1043–1048. doi:10.1038/ng.3622. PMC   5556360 . PMID   27455348. ...  Department of Neurology, Ulm University, Ulm, Germany: Bernhard Landwehrmeyer, Albert C Ludolph, Jochen H Weishaupt & Peter M Andersen ...'
  23. ↑ Fazio, Patrik; Schain, Martin; Mrzljak, Ladislav; Amini, Nahid; Nag, Sangram; Al-Tawil, Nabil; Fitzer-Attas, Cheryl J; Bronzova, Juliana; Landwehrmeyer, Bernhard; Sampaio, Cristina; Halldin, Christer; Varrone, Andrea (2017). "Patterns of age related changes for phosphodiesterase type-10A in comparison with dopamine D2/3 receptors and sub-cortical volumes in the human basal ganglia: A PET study with 18F-MNI-659 and 11C-raclopride with correction for partial volume effect" . NeuroImage. 152 (4): 330–339. doi:10.1002/mds.10229. PMID   12210870. S2CID   32410300.
  24. ↑ Wolf, Robert C; Grön, Georg; Sambataro, Fabio; Vasic, Nenad; Wolf, Nadine D; Thomann, Philipp A; Saft, Carsten; Landwehrmeyer, G Bernhard; Orth, Michael (2011). "Magnetic resonance perfusion imaging of resting-state cerebral blood flow in preclinical Huntington's disease". J Cereb Blood Flow Metab. 31 (9): 1908–18. doi:10.1038/jcbfm.2011.60. PMC   3185882 . PMID   21559028.
  25. ↑ Maier, C; Baron, R; Tölle, T R; Binder, A; Birbaumer, N; Birklein, F; Gierthmühlen, J; Flor, H; Geber, C; Huge, V; Krumova, E K; Landwehrmeyer, G B; Magerl, W; Maihöfner, C; Richter, H; Rolke, R; Scherens, A; Schwarz, A; Sommer, C; Tronnier, V l; Üçeyler, N; Valet, M; Wasner, G; Treede, D-R (2010). "Quantitative sensory testing in the German Research Network on Neuropathic Pain (DFNS): Standardized protocol and reference values" . Pain. 150 (3): 439–450. doi:10.1016/j.pain.2010.05.002. PMID   20627413. S2CID   9601884.
  26. ↑ Rolke, R; Baron, R; Maier, C; Tölle, T R; Treede, D R; Beyer, A; Binder, A; Birbaumer, N; Birklein, F; Bötefür, I C; Braune, S; Flor, H; Huge, V; Klug, R; Landwehrmeyer, G B; Magerl, W; Maihöfner, C; Rolko, C; Schaub, C; Scherens, A; Sprenger, T; Valet, M; Wasserka, B (2006). "Quantitative sensory testing in the German Research Network on Neuropathic Pain (DFNS): Somatosensory abnormalities in 1236 patients with different neuropathic pain syndromes" . Pain. 123 (3): 231–243. doi:10.1016/j.pain.2006.01.041. PMID   16697110. S2CID   44333.
  27. ↑ McAllister, Branduff; Donaldson, Jasmine; Binda, Caroline S (2022). "Exome sequencing of individuals with Huntington's disease implicates FAN1 nuclease activity in slowing CAG expansion and disease onset". Nat Neurosci. 25 (4): 446–457. doi:10.1038/s41593-022-01033-5. PMC   8986535 . PMID   35379994. ...  Department of Neurology, Ulm University, Ulm, Germany: Bernhard Landwehrmeyer ...'
  28. ↑ Goehler, Heike; Lalowski, Maciej; Stelzl, Ulrich; Waelter, Stephanie; Stroedicke, Martin; Worm, Uwe; Droege, Anja; Lindenberg, Katrin S; Knoblich, Maria; Haenig, Christian; Herbst, Martin; Suopanki, Jaana; Scherzinger, Eberhard; Abraham, Claudia; Bauer, Bianca; Hasenbank, Renate; Fritzsche, Anja; Ludewig, Andreas H; Buessow, Konrad; Coleman, Sarah H; Gutekunst, Claire-Anne; Landwehrmeyer, G Bernhard (2004). "A Protein Interaction Network Links GIT1, an Enhancer of Huntingtin Aggregation, to Huntington's Disease". Molecular Cell. 15 (6): 853–865. doi: 10.1016/j.molcel.2004.09.016 . PMID   15383276.
  29. ↑ Genetic Modifiers of Huntington's Disease (GeM-HD) Consortium (2019). "CAG Repeat Not Polyglutamine Length Determines Timing of Huntington's Disease Onset". Cell. 178 (4): 887–900. doi:10.1016/j.cell.2019.06.036. PMC   6700281 . PMID   31398342. ... Consortia <…> Group 5: Michael Orth and G. Bernhard Landwehrmeyer on behalf of the European Huntington's Disease Network (EHDN) Registry investigators; Jane S. Paulsen on behalf of the Huntington Study Group (HSG) PREDICT-HD investigators ...
  30. ↑ Genetic Modifiers of Huntington's Disease (GeM-HD) Consortium (2015). "Identification of Genetic Factors that Modify Clinical Onset of Huntington's Disease". Cell. 162 (3): 516–526. doi:10.1016/j.cell.2015.07.003. PMC   4524551 . PMID   26232222.
  31. ↑ Tabrizi, Sarah J; Reilmann, Ralf; Roos, Raymund A C; Durr, Alexandra; Leavitt, Blair; Owen, Gail; Jones, Rebecca; Johnson, Hans; Craufurd, David; Hicks, Stephen L; Kennard, Christopher; Landwehrmeyer, Bernhard; Stout, Julie C; Borowsky, Beth; Scahill, Rachael I; Frost, Chris; Langbehn, Douglas R; TRACK-HD investigators (2012). "Potential endpoints for clinical trials in premanifest and early Huntington's disease in the TRACK-HD study: analysis of 24 month observational data" . Lancet Neurol. 11 (1): 42–53. doi:10.1016/S1474-4422(11)70263-0. PMID   22137354. S2CID   34929053.
  32. ↑ Klöppel, Stefan; Gregory, Sarah; Scheller, Elisa; Minkova, Lora; Razi, Adeel; Durr, Alexandra; Roos, Raymund A C; Leavitt, Blair R; Papoutsi, Marina; Landwehrmeyer, G Bernhard; Reilmann, Ralf; Borowsky, Beth; Johnson, Hans; Mills, James A; Owen, Gail; Stout, Julie; Scahill, Rachael I; Long, Jeffrey D; Rees, Geraint; Tabrizi, Sarah J; Track-On investigators (2015). "Compensation in Preclinical Huntington's Disease: Evidence From the Track-On HD Study". eBioMedicine. 2 (10): 1420–9. doi:10.1016/j.ebiom.2015.08.002. PMC   4634199 . PMID   26629536.
  33. ↑ HORIZON Investigators of the Huntington Study Group and European Huntington's Disease Network (2013). "A Randomized, Double-blind, Placebo-Controlled Study of Latrepirdine in Patients With Mild to Moderate Huntington Disease". JAMA Neurol. 70 (1): 25–33. doi: 10.1001/2013.jamaneurol.382 . PMID   23108692. S2CID   21645327. ... *The authors for the HORIZON Investigators of the Huntington Study Group and European Huntington's Disease Network are as follows: <…> Georg B. Landwehrmeyer ...
  34. ↑ Reilmann, Ralf; McGarry, Andrew; Grachev, Igor D; Savola, Juha-Matti; Borowsky, Beth; Eyal, Eli; Gross, Nicholas; Langbehn, Douglas; Schubert, Robin; Wickenberg, Anna Teige; Papapetropoulos, Spyros; Hayden, Michael; Squitieri, Ferdinando; Kieburtz, Karl; Landwehrmeyer, G Bernhard (2019). "Safety and efficacy of pridopidine in patients with Huntington's disease (PRIDE-HD): a phase 2, randomised, placebo-controlled, multicentre, dose-ranging study" . Lancet Neurol. 18 (2): 165–176. doi:10.1016/S1474-4422(18)30391-0. PMID   30563778. S2CID   54588998.
  35. ↑ Landwehrmeyer, G. Bernhard; Dubois, Bruno; de Yébenes, Justo Garcia (2007). "Riluzole in Huntington's disease: a 3-year, randomized controlled study". Ann Neurol. 62 (3): 161–272. doi: 10.1002/ana.21181 . PMID   17702031. S2CID   23715098.
  36. ↑ Tabrizi, Sarah J; Leavitt, Blair R; Landwehrmeyer, G Bernhard (2019). "Targeting Huntingtin Expression in Patients with Huntington's Disease". N Engl J Med. 680 (24): 2307–2316. doi: 10.1056/NEJMoa1900907 . hdl: 20.500.11820/7da73cfb-3c2d-4f2e-9b92-463a6c7ad4de . PMID   31059641. S2CID   146811503.
  37. ↑ Gelderblom, Harald; Wüstenberg, Torsten; McLean, Tim; Mütze, Lisanne; Fischer, Wilhelm; Saft, Carsten; Hoffmann, Rainer; Süssmuth, Sigurd; Schlattmann, Peter; van Duijn, Erik; Landwehrmeyer, Bernhard; Priller, Josef (21 March 2017). Fasano, Alfonso (ed.). "Bupropion for the treatment of apathy in Huntington's disease: A multicenter, randomised, double-blind, placebo-controlled, prospective crossover trial". PLOS ONE. 12 (3): e0173872. Bibcode:2017PLoSO..1273872G. doi: 10.1371/journal.pone.0173872 . ISSN   1932-6203. PMC   5360242 . PMID   28323838.
  38. ↑ "Georg Bernhard Landwehrmeyer - Web of Science Citations". Publons: Track more of your research impact.
  39. ↑ "Network of Excellence in Neural Networks". CORDIS. European Commission . Retrieved 30 April 2022.
  40. ↑ "Neuroprotection and natural history in parkinson plus syndromes: a clinical trial of the efficacy and safety of riluzole in parkinson plus syndromes". CORDIS. European Commission . Retrieved 30 April 2022.
  41. ↑ "Pharmacodynamic Approaches to Demonstration of Disease-Modification in Huntington's Disease by SEN0014196". CORDIS. European Commission . Retrieved 30 April 2022.
  42. ↑ "CHDI Foundation". CHDI Foundation. CHDI Foundation . Retrieved 30 April 2022.
  43. ↑ "DOMINO-HD: Multi-Domain Lifestyle Targets for Improving ProgNOsis in Huntington's Disease" (PDF). JPND Research. Retrieved 30 April 2022.
  44. ↑ "HEALTHE-RND: European eHealth care model for rare neurodegenerative diseases" (PDF). JPND Research. Retrieved 30 April 2022.
  45. ↑ "History of the library". University Library of Tübingen . University of Tübingen . Retrieved 1 May 2022. ... 1972-1987: Richard Landwehrmeyer ...'
This page is based on this Wikipedia article
Text is available under the CC BY-SA 4.0 license; additional terms may apply.
Images, videos and audio are available under their respective licenses.